Past event: Pharmaceutical Microbiology East Coast Conference

Harnessing existing methods and novel tools in microbial control to assure continuity in product quality and patient safety

For the latest COVID-19 Travel restrictions and recommendations please click here


Microbiology remains an essential tool in reducing microbial growth in the manufacture of pharmaceuticals, to detect and eliminate microorganisms that would pose a risk to patients and jeopardise product batches.

Ensuring the sterility of the finished product continues to be one of the most critical aspects of drug development, however an array of factors are also sustaining new growth and transformation in this field. The regulatory landscape is changing, firstly with the preparation of Annex I, in addition to increasing requirements pertaining to data integrity. Light is being shed on recent product recalls for mould contamination, and infection outbreaks serve as a reminder to pay more attention to these overlooked organisms, as well as considerations towards container closure integrity testing which is being increasingly deployed to block microbe movement.

On top of this, the developing integration of automation and robotics into the manufacturing pipeline, as well as the increased need for more rapid microbiology methods brought about in part by the surge in ATMPs, are all highlighting the necessity of the field in Pharma.

This industry is ever expanding -- join leading experts in 2022 to discuss and analyse the latest advances and challenges surrounding Pharmaceutical Microbiology. Network with industry professionals, discuss revisions in regulatory and guidance documents, and gain a deeper insight into this corner of the field.

Benefits of Attending

  • REVIEW implementation guidance and validation for efficient disinfectant efficacy programs
  • UNCOVER principles in best-practice and the benefits of a robust contamination control strategy
  • ADDRESS fungal mould contamination and risk-based tools to tackle spore spreading
  • DELVE into the sterility assurance assessment and holistic closure integrity testing
  • EXPLORE the impact of the ongoing pandemic and the changing face of the pharma industry
  • UNDERSTAND new unique case studies, from contamination control as it relates to microbiome products, to risk-based assessments of traditional microbiological tests

Who should attend

  • Heads of Aseptic Processing
  • Heads of Microbiology
  • Global Quality Directors
  • Heads of GMP Compliance
  • Quality & Compliance Heads
  • Microbiology Senior Specialists
  • Directors of Quality Control Biology
  • Quality Control Managers
  • Quality Assurance Managers
  • Lean Managers
  • Operations Managers
  • Heads of Site Compliance
  • Heads of Sterile Technology
  • Global Microbiology Analytical Experts
  • Cleanroom Managers
  • Regulatory Affairs Managers
  • Production Managers
  • Quality Systems Managers

Plus Two Interactive Half Day Post-Conference Workshops | Friday 29th April 2022

Workshop A: Risk Assessment and Cleaning Validation
Workshop Leader:  
Fred Ohsiek, SME, Cleaning Validation, North America
8.30 - 12.30

Workshop B: USP Microbiology 2022 - Keeping Up with Standards

Workshop Leader:  
Donald Singer, Chair, General Chapters - Microbiology Expert Committee,
US Pharmacopeia and Ecolab Life Sciences
13.30-17.10

Speakers

  • Alison Laughlin, Associate Director, Regional Quality NA & Sterility Process Assurance, Boehringer Ingelheim
  • Dawn Watson, Director, Microbial Control, MSD
  • Donald Singer, Chair, General Chapters - Microbiology Expert Committee, Ecolab & US Pharmacopeia
  • Fred Ohsiek, Sr Manager, Global Cleaning Validation SME, Novo Nordisk
  • Hilary Chan, Principal Quality Control Scientist, Takeda
  • Jim Polarine, Senior Technical Service Manager, Head of Microbiology & Sterile Technology, STERIS Corporation; Sanofi
  • John Arigo, Division of Microbiology Assessment Director, Office of Pharmaceutical Manufacturing Assessment / FDA
  • Kate Young, Manager, QA Specialist Vector CMOs, Bristol Myers Squibb
  • Lena J Hoch, Microbiologist Specialist , GSK
  • Lynne Ensor, Vice President, RCS Head of Global Compliance, Parexel International
  • Mauro Giusti, Advisor, Site External Network, Eli Lilly Italia
  • Michael Song, Associate Director, Takeda Pharmaceutical Company Limited
  • Sean OBrien, Director, Quality Control External Operations, Seres Therapeutics
  • Stephen Yang, Director, Global Sterile / Validation COE, Merck
  • Veronika Wills, Manager, Technical Services, Associates of Cape Cod
  • Yoko Nakai, Rapid Microbiological Method RMM Research Group Representative, PDA Japan chapter

Please fill in your name and email to receive the Conference Agenda of this event.

Venue

Sheraton Boston Hotel
39 Dalton Street,
Boston, MA, USA


Event details
Organizer : SAE Media Group
Event type : Conference
Reference : ASDE-23349